后程加速超分割放射治疗合并HCPT化疗治疗中晚期食管癌疗效观察

目的评价后程加速超分割放射治疗合并HCPT化疗治疗中晚期食管癌的疗效。方法将44例收治的中晚期食管癌患者随机分为2组(单放组和化放组),每组22例。放疗均采用6MVX线外照射,单放组常规分割放射治疗2Gy/次,每天1次,全疗程总剂量60～68Gy;化放组放疗前2/3疗程常规放射治疗2Gy/次,每天1次,共40Gy,后1/3疗程改用加速超分割放射治疗,每天2次,1.1～1.2Gy/次,全疗程总剂量60～68Gy,配合HCPT化疗。治疗结束,根据食管癌放疗后X线诊断标准分级,比较两组疗效,同时比较1年生存率。并按WHO制定的药物毒性标准比较两组毒副反应。结果单放组CR为22.7%,1年生存率为50%,化放组CR为59.1%,1年生存率为81.8%,经统计学处理两者均有显著差异(P<0.05);毒副作用两组无统计学意义。结论后程加速超分割放疗加HCPT化疗能明显提高中晚期食管癌患者的近期疗效,且不增加毒副反应,远期疗效有待进一步观察。

Clinical Study of Late Course Accelerated Hyperfrationation Radiotherapy Combined with HCPT in the Treatment of Advanced Esophageal Carcinoma

Objective To evaluate the effect of late course accelerated hyperfractionation (LCAHR) plus HCPT in the treatment of advanced esophageal carcinoma. Methods 44 patients with advanced esophageal carcinoma were randomly allocated into two groups, one group received radiotherapy alone, the other group received late course accelerated hyperfractionation plus HCPT. All patients were given with 6 MV X-ray. The group received radiotherapy alone was 2 Gy per fraction, one daily, The total dose varied up to 60-68 Gy. Total tumor dose of the other group during the first two-thirds of the course was 40 Gy. 2 Gy perfraction, and followed by LCAHR, 1.1-1.2 Gy,twice daily, varied up to 60-68 Gy. Chemotherapy regimen was HCPT. Studying the efficacy and side effect between two groups. Results CR was 22.7% in the single radiotherapy group and 59.1% in the complex one.There was significant difference between two groups ( P <0.05).The 1 year survival rate in the single group and complex one were 50% and 81.8%,There also was significant difference ( P <0.05). The side effect between the two groups was not significantly improved.Conclusions LCAHR combined with HCPT was effective and well tolerant.